Sit Investment Associates Inc. reduced its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 17.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,620 shares of the biopharmaceutical company’s stock after selling 6,600 shares during the period. Sit Investment Associates Inc.’s holdings in Alexion Pharmaceuticals were worth $3,726,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of ALXN. Guardian Life Insurance Co. of America increased its position in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth $111,000. Independent Portfolio Consultants Inc. increased its position in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co increased its position in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the period. Finally, Princeton Alpha Management LP purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth $219,000. Institutional investors and hedge funds own 95.14% of the company’s stock.
Alexion Pharmaceuticals, Inc. (ALXN) opened at 138.33 on Tuesday. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.41. The stock has a market capitalization of $30.87 billion, a P/E ratio of 59.99 and a beta of 1.41. The company has a 50 day moving average of $125.22 and a 200-day moving average of $122.56.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same period in the previous year, the company posted $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. Equities research analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.57 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Sit Investment Associates Inc. Has $3.73 Million Position in Alexion Pharmaceuticals, Inc. (ALXN)” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/08/alexion-pharmaceuticals-inc-alxn-shares-sold-by-sit-investment-associates-inc-updated-updated.html.
ALXN has been the subject of a number of analyst reports. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, July 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $157.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 24th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Deutsche Bank AG cut their target price on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Five research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $156.89.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson bought 10,000 shares of the stock in a transaction on Wednesday, June 14th. The stock was purchased at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the purchase, the chief executive officer now directly owns 38,725 shares in the company, valued at $4,519,982. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The disclosure for this sale can be found here. Over the last three months, insiders have bought 2,019,734 shares of company stock worth $235,606,846. Corporate insiders own 4.35% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
